Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (121-130 of 274) with videos related to

Pageof 28
Sort By:
The Lancet. Haematology|April 12, 2016
Idiopathic multicentric Castleman's disease: a systematic literature reviewAmy Y Liu, Christopher S Nabel, Brian S Finkelman, et al.
Clinical Case Reports|April 4, 2015
Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocolsZeba N Singh, Yogesh Jethava, Ginell R Post, et al.
Blood|May 27, 2008
First thalidomide clinical trial in multiple myeloma: a decadeFrits van Rhee, Madhav Dhodapkar, John D Shaughnessy, et al.
Blood|October 7, 2006
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisFenghuang Zhan, Bart Barlogie, Varant Arzoumanian, et al.
Bone Marrow Transplantation|April 17, 2025
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experienceBhavesh Mohan Lal, Toshali Pandey, Marah Alzubi, et al.
Blood|October 20, 2007
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myelomaJumei Shi, Guido J Tricot, Tarun K Garg, et al.
Blood Neoplasia|July 24, 2024
Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccinationSaishravan Shyamsundar, Sheila K Pierson, Caoilfhionn M Connolly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's diseaseFrits van Rhee, Luis Fayad, Peter Voorhees, et al.
British Journal of Haematology|December 13, 2006
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda-Roman, Vanessa Bolejack, Varant Arzoumanian, et al.
Blood|May 16, 2009
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel, Jeff Haessler, Tracy L Y Brown, et al.
Pageof 28

Showing results (121-130 of 274) with videos related to

Sort By:
Pageof 28
The Lancet. Haematology|April 12, 2016
Idiopathic multicentric Castleman's disease: a systematic literature reviewAmy Y Liu, Christopher S Nabel, Brian S Finkelman, et al.
Clinical Case Reports|April 4, 2015
Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocolsZeba N Singh, Yogesh Jethava, Ginell R Post, et al.
Blood|May 27, 2008
First thalidomide clinical trial in multiple myeloma: a decadeFrits van Rhee, Madhav Dhodapkar, John D Shaughnessy, et al.
Blood|October 7, 2006
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisFenghuang Zhan, Bart Barlogie, Varant Arzoumanian, et al.
Bone Marrow Transplantation|April 17, 2025
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experienceBhavesh Mohan Lal, Toshali Pandey, Marah Alzubi, et al.
Blood|October 20, 2007
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myelomaJumei Shi, Guido J Tricot, Tarun K Garg, et al.
Blood Neoplasia|July 24, 2024
Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccinationSaishravan Shyamsundar, Sheila K Pierson, Caoilfhionn M Connolly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's diseaseFrits van Rhee, Luis Fayad, Peter Voorhees, et al.
British Journal of Haematology|December 13, 2006
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda-Roman, Vanessa Bolejack, Varant Arzoumanian, et al.
Blood|May 16, 2009
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel, Jeff Haessler, Tracy L Y Brown, et al.
Pageof 28